# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

> **NCT04016077** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Participants

## Interventions

- **DRUG:** PF-06651600 30 mg

## Key facts

- **NCT ID:** NCT04016077
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-19
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-03-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04016077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04016077, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04016077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*